InterventionsHumans
Recombinant Zoster Vaccine Associated with a Reduced Risk of Dementia Onset among US Beneficiaries ≥65 Years of Age
AAIC 2025 Abstract
Abstract
Background: Research showing lower risk of all‐cause dementia, Alzheimer’s Disease (AD), and vascular dementia (VD) with herpes zoster vaccination was based on one vaccine no longer marketed in the US.
The paper
Susan dosReis, Phuong TM Tran, Kareshma Mohanty, Huifeng Yun
Show 6 more authors
Alejandro Amill‐Rosario, Abree M. Johnson, Kathleen Ryan, Hannah Alsdurf, Driss Oraichi, Sofia B. Pinto,University of Maryland, Baltimore · GlaxoSmithKline (United States)
AAIC 2025 Abstract · 23 Dec 2025 · CC BY
Presented at AAIC 2025
